Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

PBI-4050 Reduces Pulmonary Hypertension, Lung fibrosis and Right Ventricular Dysfunction in Heart Failure.

Nguyen QT, Jalloul Nsaibia M, Sirois MG, Calderone A, Tardif JC, Fen Shi Y, Ruiz M, Daneault C, Gagnon L, Grouix B, Laurin P, Dupuis J.

Cardiovasc Res. 2019 Feb 7. doi: 10.1093/cvr/cvz034. [Epub ahead of print]

PMID:
30753422
2.

Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.

Khalil N, Manganas H, Ryerson CJ, Shapera S, Cantin AM, Hernandez P, Turcotte EE, Parker JM, Moran JE, Albert GR, Sawtell R, Hagerimana A, Laurin P, Gagnon L, Cesari F, Kolb M.

Eur Respir J. 2019 Mar 18;53(3). pii: 1800663. doi: 10.1183/13993003.00663-2018. Print 2019 Mar.

3.

Design and Synthesis of New 1,3,5-Trisubstituted Triazines for the Treatment of Cancer and Inflammation.

Zacharie B, Abbott SD, Duceppe JS, Gagnon L, Grouix B, Geerts L, Gervais L, Sarra-Bournet F, Perron V, Wilb N, Penney CL, Laurin P.

ChemistryOpen. 2018 Sep 21;7(9):737-749. doi: 10.1002/open.201800136. eCollection 2018 Sep.

4.

PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway.

Grouix B, Sarra-Bournet F, Leduc M, Simard JC, Hince K, Geerts L, Blais A, Gervais L, Laverdure A, Felton A, Richard J, Ouboudinar J, Gagnon W, Leblond FA, Laurin P, Gagnon L.

J Pharmacol Exp Ther. 2018 Oct;367(1):71-81. doi: 10.1124/jpet.118.250068. Epub 2018 Aug 9.

PMID:
30093459
5.

Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control.

Li Y, Chung S, Li Z, Overstreet JM, Gagnon L, Grouix B, Leduc M, Laurin P, Zhang MZ, Harris RC.

JCI Insight. 2018 May 17;3(10). pii: 120365. doi: 10.1172/jci.insight.120365. eCollection 2018 May 17.

6.

A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84.

Gagnon L, Leduc M, Thibodeau JF, Zhang MZ, Grouix B, Sarra-Bournet F, Gagnon W, Hince K, Tremblay M, Geerts L, Kennedy CRJ, Hébert RL, Gutsol A, Holterman CE, Kamto E, Gervais L, Ouboudinar J, Richard J, Felton A, Laverdure A, Simard JC, Létourneau S, Cloutier MP, Leblond FA, Abbott SD, Penney C, Duceppe JS, Zacharie B, Dupuis J, Calderone A, Nguyen QT, Harris RC, Laurin P.

Am J Pathol. 2018 May;188(5):1132-1148. doi: 10.1016/j.ajpath.2018.01.009. Epub 2018 Feb 16.

7.

Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency.

Shapiro AD, Nakar C, Parker JM, Albert GR, Moran JE, Thibaudeau K, Thukral N, Hardesty BM, Laurin P, Sandset PM.

Blood. 2018 Mar 22;131(12):1301-1310. doi: 10.1182/blood-2017-09-806729. Epub 2018 Jan 10.

8.

Coeliac disease and socio-economic status.

Stenhammar L, Högberg L, Ivarsson A, Laurin P, Myléus A, Fälth-Magnusson K.

Acta Paediatr. 2014 Aug;103(8):e328. doi: 10.1111/apa.12665. Epub 2014 May 16. No abstract available.

PMID:
24766430
9.

IgA endomysium antibodies--an early predictor for celiac disease in children without villous atrophy.

Grodzinsky E, Fälth-Magnusson K, Högberg L, Jansson G, Laurin P, Stenhammar L.

Acta Paediatr. 2008 Jul;97(7):972-6. doi: 10.1111/j.1651-2227.2008.00881.x. Epub 2008 May 16.

PMID:
18489624
10.

A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia.

Newton PN, Fernández FM, Plançon A, Mildenhall DC, Green MD, Ziyong L, Christophel EM, Phanouvong S, Howells S, McIntosh E, Laurin P, Blum N, Hampton CY, Faure K, Nyadong L, Soong CW, Santoso B, Zhiguang W, Newton J, Palmer K.

PLoS Med. 2008 Feb;5(2):e32. doi: 10.1371/journal.pmed.0050032.

11.

Urinary nitric oxide during one year of gluten-free diet with or without oats in children with coeliac disease.

Hollén E, Forslund T, Högberg L, Laurin P, Stenhammar L, Fälth-Magnusson K, Magnusson KE, Sundqvist T.

Scand J Gastroenterol. 2006 Nov;41(11):1272-8.

PMID:
17060120
12.

Coeliac children on a gluten-free diet with or without oats display equal anti-avenin antibody titres.

Hollén E, Holmgren Peterson K, Sundqvist T, Grodzinsky E, Högberg L, Laurin P, Stenhammar L, Fälth-Magnusson K, Magnusson KE.

Scand J Gastroenterol. 2006 Jan;41(1):42-7.

PMID:
16373275
13.
14.

Oats to children with newly diagnosed coeliac disease: a randomised double blind study.

Högberg L, Laurin P, Fälth-Magnusson K, Grant C, Grodzinsky E, Jansson G, Ascher H, Browaldh L, Hammersjö JA, Lindberg E, Myrdal U, Stenhammar L.

Gut. 2004 May;53(5):649-54.

15.

Increase in nitric oxide urinary products during gluten challenge in children with coeliac disease.

Laurin P, Fälth-Magnusson K, Sundqvist T.

Scand J Gastroenterol. 2003 Jan;38(1):55-60.

PMID:
12608465
16.

Even small amounts of gluten cause relapse in children with celiac disease.

Laurin P, Wolving M, Fälth-Magnusson K.

J Pediatr Gastroenterol Nutr. 2002 Jan;34(1):26-30.

PMID:
11753160
17.

Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.

Musicki B, Periers AM, Laurin P, Ferroud D, Benedetti Y, Lachaud S, Chatreaux F, Haesslein JL, Iltis A, Pierre C, Khider J, Tessot N, Airault M, Demassey J, Dupuis-Hamelin C, Lassaigne P, Bonnefoy A, Vicat P, Klich M.

Bioorg Med Chem Lett. 2000 Aug 7;10(15):1695-9.

PMID:
10937727
18.

Coumarin inhibitors of gyrase B with N-propargyloxy-carbamate as an effective pyrrole bioisostere.

Periers AM, Laurin P, Ferroud D, Haesslein JL, Klich M, Dupuis-Hamelin C, Mauvais P, Lassaigne P, Bonnefoy A, Musicki B.

Bioorg Med Chem Lett. 2000 Jan 17;10(2):161-5.

PMID:
10673102
19.

Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens.

Denis A, Agouridas C, Auger JM, Benedetti Y, Bonnefoy A, Bretin F, Chantot JF, Dussarat A, Fromentin C, D'Ambrières SG, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessot N, Pejac JM, Perron S.

Bioorg Med Chem Lett. 1999 Nov 1;9(21):3075-80.

PMID:
10560728
20.

Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B.

Laurin P, Ferroud D, Schio L, Klich M, Dupuis-Hamelin C, Mauvais P, Lassaigne P, Bonnefoy A, Musicki B.

Bioorg Med Chem Lett. 1999 Oct 4;9(19):2875-80.

PMID:
10522710
21.

Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B.

Laurin P, Ferroud D, Klich M, Dupuis-Hamelin C, Mauvais P, Lassaigne P, Bonnefoy A, Musicki B.

Bioorg Med Chem Lett. 1999 Jul 19;9(14):2079-84.

PMID:
10450985
22.

Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens.

Agouridas C, Denis A, Auger JM, Benedetti Y, Bonnefoy A, Bretin F, Chantot JF, Dussarat A, Fromentin C, D'Ambrières SG, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessot N.

J Med Chem. 1998 Oct 8;41(21):4080-100.

PMID:
9767644
23.

Significantly increased levels of nitric oxide products in urine of children with celiac disease.

Sundqvist T, Laurin P, Fälth-Magnusson K, Magnusson KE, Stenhammar L.

J Pediatr Gastroenterol Nutr. 1998 Aug;27(2):196-8.

PMID:
9702653
24.

Infant feeding history shows distinct differences between Swedish celiac and reference children.

Fälth-Magnusson K, Franzén L, Jansson G, Laurin P, Stenhammar L.

Pediatr Allergy Immunol. 1996 Feb;7(1):1-5.

PMID:
8792377
25.

Further studies on the relationship of adrenal and gonadal steroids in pubertal development in female rats.

Ducharme JR, Morera AM, Laurin P, Collu R, Audi L, Jéquier JC, Saez J.

Horm Res. 1979;10(2-3):130-42.

PMID:
155640
26.

[A typical dossier: concept of nursing sciences].

Bélanger C, Laurin P.

Auxiliaire. 1978 Jun;51(2):9-11. French. No abstract available.

PMID:
247989

Supplemental Content

Loading ...
Support Center